Vanessa Rodriguez-Fanjul
Overview
Explore the profile of Vanessa Rodriguez-Fanjul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aboudzadeh M, Rodriguez-Fanjul V, Terenzi A, Gonzalez de San Roman E, Miranda J, Pizarro A, et al.
ACS Macro Lett
. 2023 Jul;
12(7):999-1004.
PMID: 37406348
We report the synthesis of a macrocyclic poly(ethylene oxide) (PEO) connected by one [Ru(bpy)] unit (where bpy = 2,2'-bipyridine), a photoactive metal complex that provides photosensitivity and potential biomedical applications...
2.
Infante-Tadeo S, Rodriguez-Fanjul V, Vequi-Suplicy C, Pizarro A
Inorg Chem
. 2022 Nov;
61(47):18970-18978.
PMID: 36378547
Complexes of the formula [Os(η-arene)(,-phenylpyridine)Z] (where Z is chlorido or a tethered oxygen) undergo very fast Os-Z hydrolysis (<5 min), and the high basicity of the coordinated water molecule of...
3.
Rodriguez-Fanjul V, Guerrero-Lopez R, Fernandez-Varas B, Perona R, Sastre-Perona A, Sastre L
Cells
. 2022 Feb;
11(3).
PMID: 35159320
Colorectal cancer is the second most common cancer in women, the third in men, and an important cause of cancer-related mortality. Recurrence and the development of chemotherapy resistance are major...
4.
Infante-Tadeo S, Rodriguez-Fanjul V, Habtemariam A, Pizarro A
Chem Sci
. 2021 Aug;
12(27):9287-9297.
PMID: 34349898
Aquation is often acknowledged as a necessary step for metallodrug activity inside the cell. Hemilabile ligands can be used for reversible metallodrug activation. We report a new family of osmium(ii)...
5.
Carrasco A, Rodriguez-Fanjul V, Pizarro A
Inorg Chem
. 2020 Oct;
59(22):16454-16466.
PMID: 33103884
We present four new organometallic half-sandwich iridium(III) complexes of formula [Ir(η:κ-CMeCHpy)(N,N)](PF), bearing a N,N-chelating ligand [ethylenediamine (en), ; 1,3-diaminopropane (dap), ; 2,2'-bipyridine (bipy), ; 1,10-phenanthroline (phen), ]; and a derivatized...
6.
Carrasco A, Rodriguez-Fanjul V, Habtemariam A, Pizarro A
J Med Chem
. 2020 Mar;
63(8):4005-4021.
PMID: 32207946
Six complexes of formula [Ir(η:κ-CMeCHpy)(C,N)]PF, where CMeCHpy is 2-((2,3,4,5-tetramethylcyclopentadienyl)methyl)pyridine, and C,N is 2-phenylpyridine (), 7,8-benzoquinoline (), 1-phenylisoquinoline (), 2-(-tolyl)pyridine (), 4-chloro-2-phenylquinoline (), or 2-(2,4-difluorophenyl)pyridine (), have been synthesized. The cyclopentadienyl...
7.
Conesa J, Carrasco A, Rodriguez-Fanjul V, Yang Y, Carrascosa J, Cloetens P, et al.
Angew Chem Int Ed Engl
. 2019 Nov;
59(3):1270-1278.
PMID: 31697000
The iridium half-sandwich complex [Ir(η :κ -C Me CH py)(2-phenylpyridine)]PF is highly cytotoxic: 15-250× more potent than clinically used cisplatin in several cancer cell lines. We have developed a correlative...
8.
Rodriguez-Fanjul V, Lopez-Torres E, Mendiola M, Pizarro A
Eur J Med Chem
. 2018 Feb;
148:372-383.
PMID: 29471123
Gold(III) compounds have received increasing attention in cancer research. Three gold complexes of general formula [AuL]Cl, where L is benzil bis(thiosemicarbazonate), compound 1, benzil bis(4-methyl-3-thiosemicarbazonate), compound 2, or benzil bis(4-cyclohexyl-3-thiosemicarbazonate),...
9.
Garcia-Romero N, Gonzalez-Tejedo C, Carrion-Navarro J, Esteban-Rubio S, Rackov G, Rodriguez-Fanjul V, et al.
Oncotarget
. 2016 Sep;
7(40):65888-65901.
PMID: 27589567
Human gliomas harbour cancer stem cells (CSCs) that evolve along the course of the disease, forming highly heterogeneous subpopulations within the tumour mass. These cells possess self-renewal properties and appear...
10.
Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, et al.
Cancer Lett
. 2009 Jun;
286(2):206-16.
PMID: 19553005
Treatment of non-small cell lung cancer (NSCLC) with cisplatin has a level of antitumor activity still modest. We have shown previously that MKP1/DUSP1 inhibits cisplatin-induced apoptosis in NSCLC cells and...